Please assess the completion status of the following clinical trial:

Trial Title: Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 65 years~* Age \< 65 but not eligible to high-dose chemotherapy and autologous stem cell transplantation~* Biopsy-proven DLBCL relapsed to previous combination chemotherapy regimen ± rituximab~* PR (Partial Response) or CR (Complete Response) to second-line chemotherapy (ICE or DHAP/DHAOx or MINE regimen) + rituximab~* ECOG (Eastern Cooperative Oncology Group) performance status score \< 4~* Female of childbearing potential (FCBP) must demonstrate to practice a proper contraception to avoid any pregnancy risk during the study and at least 28 days after the discontinuation of the study~* Male subjects must agree to practice a proper contraception during any sexual contact with females childbearing potential~Exclusion Criteria:~* CNS (Central Nervous System) involvement~* Prior ASCT~* TTP (Time To Progression) \<6 months after first-line therapy~* Use of experimental drugs during second-line salvage chemotherapy~* Severe concomitant illnesses / medical conditions (e.g. impaired respiratory and/or cardiac function, uncontrolled diabetes mellitus )~* Active infectious disease~* HIV, HBV (Hepatitis B Virus) or HCV (Hepatitis C Virus) - positivity~* Impaired liver function (Bilirubin \>2 x upper normal limit; ALT (alanine aminotransferase) /AST (aspartate aminotransferase) /GGT (γ-glutamyltransferase) \> 3 x upper normal limit) at one month from salvage chemotherapy conclusion~* Impaired renal function (creatinine clearance \<50 ml/min) at one month from salvage chemotherapy conclusion~* Absolute neutrophil count (ANC) \<1000/microL~* Platelet count \<75.000 /mm3~* Hemoglobin \<9 g/dL~* Non-co-operative behaviour or non-compliance~* Psychiatric diseases or conditions that might impair the ability to give informed consent~* Pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide (Type: EXPERIMENTAL): single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.

Based on this trial design, predict the completion outcome and termination type (if applicable).